Business Context and Reporting Period
Company: Standard BioTools Inc. (Nasdaq: LAB)
Filing Type: Form 10-Q (Unaudited)
Period: Three months ended March 31, 2026
Business Overview: The Company develops and sells instrumentation, consumables, and services for proteomics and genomics research. A major strategic shift occurred in Q1 2026 with the completion of the sale of its SomaScan Business (aptamer-based and functional proteomics) to Illumina, Inc. on January 30, 2026. This transaction is classified as discontinued operations. The Company retained its mass cytometry and microfluidics businesses as continuing operations.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue (Continuing Ops) | $21,146 | $20,222 |
| Gross Profit | $11,308 | $11,049 |
| Gross Margin | 53.5% | 54.6% |
| Net Loss from Continuing Operations | $(14,626) | $(23,370) |
| Net Income (Loss) (Including Discontinued Ops) | $127,068 | $(26,033) |
| Cash and Cash Equivalents | $265,772 | $120,863 |
| Total Investments (Short & Long Term) | $260,761 | $92,413 |
| Net Cash Used in Operating Activities | $(46,597) | $(30,283) |
| Net Cash Provided by Investing Activities | $191,090 | $14,625 |
Note: Net Income for Q1 2026 is driven by a $172.3 million pre-tax gain on the sale of the SomaScan Business, reported within discontinued operations.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue from continuing operations increased 5% year-over-year to $21.1 million. This was driven by a 35% increase in consumables revenue ($10.98M vs $8.14M), partially offset by a 33% decline in instrument sales ($4.47M vs $6.65M) due to macroeconomic pressures and customer budget constraints.
- Operating Expenses: Total operating expenses decreased 37% to $23.8 million. Significant reductions were seen in R&D (down 61%) and SG&A (down 38%) due to restructuring activities and workforce reductions initiated in late 2025.
- Restructuring Charges: Restructuring and related charges increased 98% to $3.1 million, primarily due to facility costs associated with vacating the South San Francisco office and severance payments.
- Liquidity Position: Cash and investments increased significantly to $526.5 million (from $213.3 million at year-end 2025) following the receipt of $363.2 million in net cash proceeds from the SomaScan divestiture.
- Discontinued Operations: The Company recognized a $172.3 million gain on the sale of the SomaScan Business, resulting in a net income from discontinued operations of $141.7 million.
Guidance, Outlook, Risks, and Unusual Items
- Divestiture Impact: The sale of the SomaScan Business to Illumina closed on January 30, 2026. The Company received $363.2 million in cash and a $25.0 million contingent receivable. Future earnout payments of up to $50.0 million are possible based on 2026 revenue thresholds. The Company also secured royalty streams on specific products.
- Restructuring: The Company completed a consolidation of R&D capabilities into Singapore and vacated its South San Francisco headquarters. Combined workforce reductions impacted approximately 20% of the global workforce.
- Nasdaq Listing Risk: On April 20, 2026, the Company received notice from Nasdaq that its stock price had fallen below the $1.00 minimum bid price requirement for 30 consecutive days. The Company has 180 days (until October 19, 2026) to regain compliance. Failure to do so could result in delisting.
- Legal Proceedings: The Company is involved in stockholder litigation regarding the prior SomaLogic merger and a Palamedrix litigation matter. An accrual of $3.3 million has been recorded for indemnification obligations related to the Palamedrix suit.
- Outlook: Management expects existing liquidity to support operations for at least the next 12 months. The focus remains on cost structure optimization and growing the installed base of instruments to drive consumables revenue.
Investor Verification Checklist
- Delisting Risk: Verify the Company's progress in regaining compliance with Nasdaq's $1.00 minimum bid price requirement by the October 19, 2026 deadline.
- Continuing Operations Viability: Assess the sustainability of the core business (mass cytometry and microfluidics) excluding the one-time gain from discontinued operations, given the ongoing operating losses from continuing operations.
- Restructuring Execution: Monitor the realization of cost savings from the 20% workforce reduction and facility consolidation to ensure they offset the decline in instrument sales.
- Contingent Consideration: Track the achievement of revenue thresholds required to realize the $25.0 million receivable and potential $50.0 million earnout from the Illumina transaction.
- Legal Exposure: Review updates on the Palamedrix litigation and the SomaLogic stockholder lawsuit to ensure the $3.3 million accrual remains sufficient and no new material liabilities arise.